indazoles has been researched along with Cancer of the Urinary Tract in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, L; Bahl, A; Birtle, A; Chakraborti, P; Crabb, SJ; Dixon-Hughes, J; Huddart, RA; Hussain, SA; Jagdev, S; Jones, RJ; Kelly, C; Morris, A; Paul, J; Powles, T; Protheroe, AS; Stobo, J; Stockdale, A; Sundar, S | 1 |
| Kelly, C; Paul, J; Powles, T; Stobo, J | 1 |
| Horiguchi, M; Uno, H; Wei, LJ | 1 |
| Arndt, C; Ecke, TH; Eimer, C; Georgas, E; Gerullis, H; Otto, T | 1 |
| Jones, R | 1 |
| Erlichman, C; Flynn, PJ; Ho, WM; Miles, KM; Millward, M; Picus, J; Pili, R; Pitot, H; Qin, R; Tan, W; Vaishampayan, U | 1 |
| Crippa, F; Daidone, MG; De Braud, FG; Farè, E; Giannatempo, P; Gianni, AM; Landoni, E; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Raggi, D; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N | 1 |
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G | 1 |
| Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U | 1 |
| Galsky, MD | 1 |
| Crippa, F; Daidone, MG; De Braud, F; Giannatempo, P; Gianni, AM; Lanocita, R; Mariani, L; Messina, C; Morosi, C; Necchi, A; Nicolai, N; Ortega, C; Pennati, M; Sacco, C; Salvioni, R; Sava, T; Schwartz, LH; Zaffaroni, N | 1 |
6 trial(s) available for indazoles and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Urologic Neoplasms | 2017 |
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Humans; Indazoles; Male; Neutropenia; Organoplatinum Compounds; Palliative Care; Prospective Studies; Pyrimidines; Salvage Therapy; Sulfonamides; Thrombocytopenia; Urologic Neoplasms; Vinblastine | 2013 |
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure; Urologic Neoplasms; Urothelium | 2013 |
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; Indazoles; Interleukin-8; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Urologic Neoplasms | 2014 |
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Tumor Burden; Urologic Neoplasms; Urothelium | 2012 |
5 other study(ies) available for indazoles and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Reply to M. Horiguchi et al.
Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms | 2017 |
Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms | 2017 |
Urological medical oncology: land of opportunity.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomedical Research; Clinical Trials, Phase III as Topic; Humans; Indazoles; Medical Oncology; Pyrimidines; Scotland; Sulfonamides; Urologic Neoplasms; Urology | 2013 |
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma.
Topics: Angiopoietins; Animals; Carbazoles; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Indazoles; Mice; Mice, Nude; Random Allocation; Receptor, TIE-2; Signal Transduction; Urologic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Antiangiogenic treatment in metastatic urothelial cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Male; Pyrimidines; Sulfonamides; Urologic Neoplasms; Urothelium | 2012 |